Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
QRxPharma Successfully Completes Comparative Study for Dual-Opioid Pain Therapy
May 15th, 2009
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced the successful completion of a Phase 3 program pilot study comparing the efficacy and safety profile of MoxDuo IR against component doses of morphine and oxycodone. Results demonstrated that MoxDuo IR reduces pain significantly more than its component doses; further, when compared to equianalgesic doses of morphine and oxycodone, MoxDuo IR produced fewer and less intense side effects. These results confirm 12mg/8mg morphine plus oxycodone combination as the preferred dose for optimal efficacy and tolerability as well as provide sample size guidance for the upcoming Phase 3 Combination Rule study required for...
Source: Health Business Week (2009-05-15)
|
